The project carried out a comprehensive set of scientific and technical activities to transition GLIX1 from advanced preclinical development to full clinical readiness. A complete non-clinical development program was executed, including pharmacokinetic characterization and GLP-compliant repeated-dose toxicology studies in rat and dog, supported by validated bioanalytical methods and toxicokinetic assessments. These studies defined systemic exposure, bioavailability, safety margins, and dose rationale, generating the regulatory-grade data package required for human entry. All non-clinical reports were finalized, quality assured, and formally accepted, establishing the safety foundation for clinical testing.
On the regulatory and translational side, the project prepared the full clinical documentation set, including the Investigator’s Brochure, clinical protocol, and integrated non-clinical summaries, culminating in successful submission and clearance of a U.S. FDA Investigational New Drug (IND) application. This outcome represents formal regulatory authorization to initiate first-in-human testing. In parallel, GMP manufacturing of clinical drug substance and drug product was completed, with formulation into oral capsules, QA/QP release, and long-term stability data supporting a shelf life of up to two years. Clinical material is therefore available and technically ready for trial use. Clinical site agreements and informed consent documentation were finalized, enabling operational readiness for trial initiation once enrollment begins.
A companion diagnostic (CDx) strategy was scientifically evaluated through prototype kit development and extensive analytical and biological verification studies, including biomarker correlation analyses across cell models and transcriptomic datasets. The outcome demonstrated that the investigated biomarker approach did not provide a technically or clinically actionable correlation with GLIX1 response. As a result, CDx development was discontinued based on validated negative findings, preventing inefficient downstream investment and allowing full focus on therapeutic development without impacting the core clinical objective.
Overall, the main technical achievements are: completion of the full non-clinical safety and pharmacokinetic package; establishment of clinical dose rationale; successful GMP manufacture and quality release of clinical material; regulatory clearance to proceed to human trials; and validated resolution of the CDx feasibility question. Together, these outcomes move GLIX1 across the critical translational threshold from preclinical research into regulatory and operational readiness for first-in-human clinical evaluation.
